CMA1 Antibody (Center) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | P23946 |
---|---|
Clone Names | 80410117 |
Gene ID | 1215 |
---|---|
Other Names | Chymase, Alpha-chymase, Mast cell protease I, CMA1, CYH, CYM |
Target/Specificity | The synthetic peptide sequence used to generate the antibody AP7655c was selected from the Center region of human CMA1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | CMA1 |
---|---|
Synonyms | CYH, CYM |
Function | Major secreted protease of mast cells with suspected roles in vasoactive peptide generation, extracellular matrix degradation, and regulation of gland secretion. |
Cellular Location | Secreted. Cytoplasmic granule. Note=Mast cell granules |
Tissue Location | Mast cells in lung, heart, skin and placenta. Expressed in both normal skin and in urticaria pigmentosa lesions |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
CMA1 is a chymotryptic serine proteinase that belongs to the peptidase family S1. It is expressed in mast cells and thought to function in the degradation of the extracellular matrix, the regulation of submucosal gland secretion, and the generation of vasoactive peptides. In the heart and blood vessels, this protein, rather than angiotensin converting enzyme, is largely responsible for converting angiotensin I to the vasoactive peptide angiotensin II. Angiotensin II has been implicated in blood pressure control and in the pathogenesis of hypertension, cardiac hypertrophy, and heart failure. Thus, this protein is a target for cardiovascular disease therapies.
References
Raymond,W.W., J. Immunol. 182 (9), 5770-5777 (2009)Chung,W.K., J. Heart Lung Transplant. 28 (4), 373-379 (2009)Hossny,E.M., J Investig Allergol Clin Immunol 18 (5), 376-381 (2008)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.